Celldex Therapeutics Presents Positive Data from
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape -- At...
Source: globenewswire.com
📰 Complete Response News
Page 5 - Complete Response News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Complete Response. Real-time updates on events, politics, business and more.
Johnson & Johnson : Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 ... | June 5, 2023
Source: marketscreener.com
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
Real-World Results Demonstrate Objective Response Rate of 67% in 24 EBV+ PTLD Patients 91% Overall Survival at One Year for Patients Responding to Tab-cel Compared to 34% for... | June 5, 2023
Source: marketscreener.com
ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer
/PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical...
Source: prnewswire.com
ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer
YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago. Researchers tested disitamab vedotin and toripalimab in combination on...
Source: asiaone.com
Allogene Therapeutics, Inc.: Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused
United States Christine Cassiano Allogene Allo Madeleine Goldstein Zachary Roberts Drug Administration
Source: finanznachrichten.de
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation... | June 3, 2023
United States Allogene Allo Madeleine Goldstein Zachary Roberts Christine Cassiano American Society Of Clinical Oncology
Source: marketscreener.com
Allogene Therapeutics Presents Updated ALLO-501/501A Phase
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to...
United States Madeleine Goldstein Allogene Allo Zachary Roberts Christine Cassiano European Hematology Association
Source: globenewswire.com
Theralase Technologies Inc.: Theralase Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release.TORONTO, ON / ACCESSWIRE / May 30, 2023 / Theralase®
United States San Francisco Roger Dumoulin White Arkady Mandel Regulation Services Provider Venture Exchange
Source: finanznachrichten.de
Theralase Technologies Inc.: Theralase Releases 1Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / May 30 2023 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development
United States San Francisco Roger Dumoulin White Arkady Mandel Clean Technology American Urology Association
Source: finanznachrichten.de